Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia.

Paiboonrungruang C, Xiong Z, Lamson D, Li Y, Bowman B, Chembo J, Huang C, Li J, Livingston EW, Frank JE, Chen V, Li Y, Weissman B, Yuan H, Williams KP, Ben Major M, Chen X. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia. Redox Biol. 2023 11; 67:102901.

View in: PubMed

subject areas

Animals
Cell Line, Tumor
Cell Proliferation
Esophageal Neoplasms
Humans
Hyperplasia
Mice
NF-E2-Related Factor 2
Pyrimethamine

authors with profiles

Kevin Williams

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support